Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin-Reference-Cited by-同舟云学术

Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin

Published:2018-08-25 Issue:6 Volume:18 Page:503-511
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Silvain Johanne, ,O’Connor Stephen A.,Yan Yan,Kerneis Mathieu,Hauguel-Moreau Marie,Zeitouni Michel,Overtchouk Pavel,Ankri Annick,Brugier Delphine,Vicaut Eric,Ecollan Patrick,Galier Sophie,Collet Jean-Philippe,Montalescot Gilles

Funder

Action Coeur

Sanofi-Aventis

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/article/10.1007/s40256-018-0294-z/fulltext.html

Reference27 articles.

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

2. Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;3(344):e553.